alexa Combination Epigenetic Therapy For Recurrent Platinum Resistant-platinum Refractory Epithelial Ovarian Cancer
ISSN: 2161-0932

Gynecology & Obstetrics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

2nd International Congress on Contemporary Issues in Women Cancers & Gynecologic Oncology
August 29-30, 2017 | London, UK

Samir A Farghaly
Cornell University, USA
Keynote: Gynecol Obstet (Sunnyvale)
DOI: 10.4172/2161-0932-C1-017
Abstract
Ovarian cancer is the most lethal gynecologic malignancy. Epithelial ovarian cancer (EOC) which is the most common histologic type has 5-year survival for all stages at 45.6%. This rate increases are about 70% in the minority of patients who are diagnosed at an early stage, but declines to 35% in most patients diagnosed at advanced stage. The standard treatment is primary surgery followed by platinum-based chemotherapy. In recurrent platinum-resistant/platinum-refractory EOC, sequential single-agent salvage chemotherapy is the standard of therapy, however none achieves the desired prognostic and curative effect. Currently, the impact of targeted therapies and immunotherapies on progression-free survival and overall survival, is under investigation. A new treatment modality is needed to achieve satisfactory oncologic outcomes. Triple therapy; sensitization for immune checkpoint therapy following combined inhibition of DNMT1 and EZH2 induces ovarian cancer cells to express CXC-motif chemokine 9 (CXCL9) and CXCL10, which can stimulate T helper 1 cells. This chemokine upregulation induces the attraction of tumourinfiltrating lymphocytes (TILs), which leads to the killing of tumor cells when combined with immune checkpoint therapy such as CTLA4 immune check antibody. This regimen demonstrated significant therapeutic synergy and durable treatment responses. In conclusion, the epigenetic drugs target the epigenome, and this lessens the need for precision approaches to individualized cancer therapy.
Biography

Samir A Farghaly is a Professor/Physician/Scientist and national and international expert in Obstetrics and Gynecology at Joan and Sanford I Weill College of Medicine, Sandra and Edward Meyer Cancer Center and, the New York Presbyterian Hospital/Weill Cornell Medical Center- Cornell University, New York, USA. He has received his MD from London University and his PhD degree in Molecular Biology from London University. He was affiliated with major London University teaching hospitals, Columbia University College of Physicians and Surgeons/Columbia University Medical Center, New York, USA. He has been an invited speaker at several national and international conferences on Women’s Health, Molecular Genetics of Female Cancers, Gynecological Cancer, and Oncologic Radical Surgical Techniques. He is a member of several national and international societies, organizations, foundations of Women Health and Cancer. He is the founding Editor-in Chief of Insights in Gynecologic Oncology Journal, and Enliven Challenges in Cancer Detection and Therapy Journal. He acts as Senior Editor/Editor and member of editorial boards, editorial advisory boards of 18 international medical journals on Gynecological Cancers, Gene expression and Therapy, Women’s Health, and Gynecology. He acted as Guest Editor of 4 special issues of international medical journals on Oncology, Gynecology and Gene Therapy. He is a reviewer for several medical journals on Obstetrics & Gynecology, Molecular Genetics and Therapy, Oncology, and Surgery. He has published 105 articles in reputed peer review journals. He has written several book chapters, and is an author and editor of (2) books on Ovarian Cancer published in 2012, and the third one published in Nov. 2013. The fourth book on Endometrial Cancer was published in January 2015. The fifth book on Recent Advances in Diagnosis and Management Gynecologic Cancers was published in March 2016, the sixth book on Ovarian Cancer Immunotherapy will be published in November 2017, and the seventh book on Uterine Cervical Cancer will be published in Feb. 2018.

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version